AMNEAL PHARMACEUTICALS INC (AMRX) Stock Price & Overview
NASDAQ:AMRX • US03168L1052
Current stock price
The current stock price of AMRX is 12.48 USD. Today AMRX is down by -1.81%. In the past month the price decreased by -5.88%. In the past year, price increased by 69.11%.
AMRX Key Statistics
- Market Cap
- 3.927B
- P/E
- 14.86
- Fwd P/E
- 12.80
- EPS (TTM)
- 0.84
- Dividend Yield
- N/A
AMRX Stock Performance
AMRX Stock Chart
AMRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AMRX. When comparing the yearly performance of all stocks, AMRX is one of the better performing stocks in the market, outperforming 84.34% of all stocks.
AMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMRX. AMRX has an excellent profitability rating, but there are some minor concerns on its financial health.
AMRX Earnings
On February 27, 2026 AMRX reported an EPS of 0.21 and a revenue of 814.32M. The company beat EPS expectations (11.53% surprise) and missed revenue expectations (-1.18% surprise).
AMRX Forecast & Estimates
11 analysts have analysed AMRX and the average price target is 16.83 USD. This implies a price increase of 34.86% is expected in the next year compared to the current price of 12.48.
For the next year, analysts expect an EPS growth of 16.11% and a revenue growth 3.71% for AMRX
AMRX Groups
Sector & Classification
AMRX Financial Highlights
Over the last trailing twelve months AMRX reported a non-GAAP Earnings per Share(EPS) of 0.84. The EPS increased by 44.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.39% | ||
| ROA | 1.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AMRX Ownership
AMRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.764B | ||
| PFE | PFIZER INC | 9.48 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 125.711B | ||
| ZTS | ZOETIS INC | 16.66 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 27.972B | ||
| VTRS | VIATRIS INC | 5.36 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMRX
Company Profile
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Company Info
IPO: 2009-11-18
AMNEAL PHARMACEUTICALS INC
400 Crossing Boulevard, 3rd Floor
Bridgewater NEW JERSEY 08807 US
CEO: Chirag Patel
Employees: 8500
Phone: 19089473120
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What does AMRX do?
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
What is the current price of AMRX stock?
The current stock price of AMRX is 12.48 USD. The price decreased by -1.81% in the last trading session.
What is the dividend status of AMNEAL PHARMACEUTICALS INC?
AMRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AMRX stock?
AMRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for AMRX stock?
11 analysts have analysed AMRX and the average price target is 16.83 USD. This implies a price increase of 34.86% is expected in the next year compared to the current price of 12.48.
Is AMNEAL PHARMACEUTICALS INC (AMRX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AMRX.